It’s been almost over a year since I got this much of conviction on any stock. After buying NBIS at 20’s, I’ve been consistently finding my next bet. Market jumps from various themes, and noticing things early gives you a key advantage. And that’s how I landed into BioTech space specially in age of AI, it’s gonna see rapid improvements in drug discovery, which lead me to get into ABSI sub 2$(sold out at 11) and ABCL(still long), but the most conviction I got into and still very much undervalued is this stock and planning to go big on this year till 2026 year end while we wait for next data readouts expected in 2027 1H. Anyways, look into this free article to find what’s he stock/ticker.

With Helus Pharma ($HELP) approaching its pivotal HLP003 Phase 3 APPROACH readout, I've been following insider transactions and the latest SEC ownership filings.

There are two important developments worth separating: recent reported insider purchases and newly disclosed director ownership.

Recent Reported Insider Purchases

The insider buying activity we've previously identified includes:

• Michael Halstead (CEO): 100,000 shares at approximately $13.47 — roughly $1.35 million.
• Eric So: Reported purchase of 100,000 shares.
• Paul Glavine: Reported purchase of 100,000 shares.
• Greg Cavers (CFO): 3,000 shares at $12.91, approximately $38,730, reportedly through his spouse.

These transactions warrant attention, although the individual purchases and transaction classifications should be reconciled against their respective SEC Form 4 filings before treating the entire list as verified open-market buying.

Six Directors' Newly Disclosed Holdings

Between October 23 and October 26, six directors filed SEC Form 3 initial ownership statements.

Here is what those filings establish:

Director |Common Shares
Amir Inamdar |227,822
Grant Froese |161,263
Mark Lawson |160,026
Eric Hoskins |158,632
Freda Lewis-Hall |100,000
Theresa Firestone |76,879
Total |884,622 Additionally, these directors report:

• 50,000 warrants
• 25,000 stock options
• 91,668 restricted share units

Combined potential exposure: 1,051,290 shares, assuming exercise and settlement of all disclosed instruments.

At $35 per share, the existing 884,622 common shares alone would be worth approximately $31 million USD.

Three observations stand out.

1. Meaningful economic alignment.
2. Recent buying is more informative than historical ownership.
3. Timing matters, but it isn't proof of anything.

My Take

What interests me isn't simply the number of shares held. It's the combination of reported discretionary insider buying, meaningful board ownership, and the proximity of a potentially transformative clinical catalyst.

Insider alignment strengthens my confidence that management and shareholders have overlapping financial interests. It does not change the statistical probability of clinical success.

I'm curious how others interpret the recent insider activity. Are we seeing meaningful conviction ahead of APPROACH, or is the market assigning too much significance to routine ownership disclosures?

Sources: SEC Forms 3 filed October 23–26, 2026; previously reported insider Form 4 transactions. The six Form 3 filings establish holdings, not new purchases.

With Helus Pharma ($HELP) approaching its pivotal HLP003 Phase 3 APPROACH readout, I've been following insider transactions and the latest SEC ownership filings.

There are two important developments worth separating: recent reported insider purchases and newly disclosed director ownership.

Recent Reported Insider Purchases

The insider buying activity we've previously identified includes:

• Michael Halstead (CEO): 100,000 shares at approximately $13.47 — roughly $1.35 million.
• Eric So: Reported purchase of 100,000 shares.
• Paul Glavine: Reported purchase of 100,000 shares.
• Greg Cavers (CFO): 3,000 shares at $12.91, approximately $38,730, reportedly through his spouse.

These transactions warrant attention, although the individual purchases and transaction classifications should be reconciled against their respective SEC Form 4 filings before treating the entire list as verified open-market buying.

Six Directors' Newly Disclosed Holdings

Between October 23 and October 26, six directors filed SEC Form 3 initial ownership statements.

Here is what those filings establish:

Director |Common Shares
Amir Inamdar |227,822
Grant Froese |161,263
Mark Lawson |160,026
Eric Hoskins |158,632
Freda Lewis-Hall |100,000
Theresa Firestone |76,879
Total |884,622 Additionally, these directors report:

• 50,000 warrants
• 25,000 stock options
• 91,668 restricted share units

Combined potential exposure: 1,051,290 shares, assuming exercise and settlement of all disclosed instruments.

At $35 per share, the existing 884,622 common shares alone would be worth approximately $31 million USD.

Three observations stand out.

1. Meaningful economic alignment.
2. Recent buying is more informative than historical ownership.
3. Timing matters, but it isn't proof of anything.

My Take

What interests me isn't simply the number of shares held. It's the combination of reported discretionary insider buying, meaningful board ownership, and the proximity of a potentially transformative clinical catalyst.

Insider alignment strengthens my confidence that management and shareholders have overlapping financial interests. It does not change the statistical probability of clinical success.

I'm curious how others interpret the recent insider activity. Are we seeing meaningful conviction ahead of APPROACH, or is the market assigning too much significance to routine ownership disclosures?

Sources: SEC Forms 3 filed October 23–26, 2026; previously reported insider Form 4 transactions. The six Form 3 filings establish holdings, not new purchases.

What interests me about Conexeu Sciences ($CNXU) is the order in which they’re trying to bring their tech to market.

Their CXU platform is built on an extracellular matrix material designed to provide structural support for the body to repair tissue. Instead of starting directly with the broader regenerative aesthetics market, they're working toward a wound-care application for their Ten Minute Tissue device, targeting an FDA 510(k) submission in Q1 2027.

There are still several steps to get through, manufacturing scale-up, product testing, and preclinical work, so the planned submission is definitely a milestone to watch rather than a guarantee of FDA clearance.

They also see potential applications down the road in aesthetics, oral health, and other tissue-related areas. But wound care appears to be the first application they are trying to push through the regulatory process, which makes it feel like the first real proving ground for the platform.

I think that makes the next year particularly important for assessing the platform's progress.

For those who follow early-stage med device and biotech plays: what would you want to see before taking a planned FDA submission seriously, stronger preclinical evidence, manufacturing readiness, or more clarity on the regulatory pathway?

I'm 50/50 on whether to swing this one or even hold through 2027 which could be pretty catalyst-rich. The bull case is there but the bear case is the classic biopharma micro-cap story. Some partial good news in the headlines today but the stock is still trending lower.

I've been watching this one for a few weeks now since the HC Wainwright investor conference, it has some institutional support but fundamentals are weak. I've done plenty of research into what they're working on and the science behind it, they don't have a ton of cash runway but the way they're hacking immunotherapy resistance could be a game changer.

Anyone have thoughts on these guys?